--- title: "GLP-1 vs DPP-4 India" description: "GLP-1 vs DPP-4 inhibitors in India: weight effects, hypoglycaemia risk, cost, RSSDI pathways, and when endocrinologists escalate beyond DPP-4." canonical: "https://www.kesho.health/keywords/glp-1-vs-dpp4-india" markdown_url: "https://www.kesho.health/md/keywords/glp-1-vs-dpp4-india" language: "en-IN" primary_keyword: "GLP-1 vs DPP-4 India" --- # GLP-1 vs DPP-4 inhibitors — India comparison > **Short answer:** DPP-4 inhibitors (gliptins) are oral, weight-neutral diabetes medicines with low hypoglycaemia risk—often first add-ons after metformin. GLP-1 receptor agonists deliver stronger weight and HbA1c effects but cost more and require injection or strict oral semaglutide rules. RSSDI pathways guide escalation under specialist supervision. **Canonical HTML:** https://www.kesho.health/keywords/glp-1-vs-dpp4-india **Markdown:** https://www.kesho.health/md/keywords/glp-1-vs-dpp4-india ## Drug-class choice **Free lab prep scan** — Upload your lab report and get a personalised checklist for your endocrine visit — HbA1c, lipids, kidney function, and questions to ask. [Free lab prep scan](https://www.kesho.health/lab-prep-scan) **Find a specialist** — Legitimate endocrinologist and diabetologist pathways in your city — Kesho does not take bookings or list individual doctors. [Find a specialist](https://www.kesho.health/find-specialist) ## How do GLP-1 and DPP-4 differ mechanistically? GLP-1 receptor agonists mimic incretin hormones with strong appetite effects; DPP-4 inhibitors block enzyme breakdown of native GLP-1 with milder metabolic impact. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised decisions. Kesho provides drug-class education only—not prescribing advice. Verify CDSCO approval and Schedule H prescriptions at licensed Indian pharmacies before every refill. RSSDI and ICMR guidance emphasise structured lifestyle support alongside pharmacotherapy for South Asian metabolic risk. Document HbA1c, waist circumference, and weight trends for follow-up visits in metro and tier-2 Indian practice. ## Which drug class reduces weight more in Indian patients? GLP-1 class medicines typically produce greater weight reduction—relevant for thin-fat South Asian phenotypes with high visceral fat despite modest BMI. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised decisions. Kesho provides drug-class education only—not prescribing advice. Verify CDSCO approval and Schedule H prescriptions at licensed Indian pharmacies before every refill. RSSDI and ICMR guidance emphasise structured lifestyle support alongside pharmacotherapy for South Asian metabolic risk. Document HbA1c, waist circumference, and weight trends for follow-up visits in metro and tier-2 Indian practice. ## How does hypoglycaemia risk compare? DPP-4 inhibitors rarely cause hypoglycaemia alone; GLP-1 combinations with sulfonylureas require dose adjustments—discuss at every follow-up. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised decisions. Kesho provides drug-class education only—not prescribing advice. Verify CDSCO approval and Schedule H prescriptions at licensed Indian pharmacies before every refill. RSSDI and ICMR guidance emphasise structured lifestyle support alongside pharmacotherapy for South Asian metabolic risk. Document HbA1c, waist circumference, and weight trends for follow-up visits in metro and tier-2 Indian practice. ## What are typical monthly cost differences in India? Gliptins often cost less monthly than injectable semaglutide or tirzepatide—budget planning should compare multi-year totals not first-month quotes alone. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised decisions. Kesho provides drug-class education only—not prescribing advice. Verify CDSCO approval and Schedule H prescriptions at licensed Indian pharmacies before every refill. RSSDI and ICMR guidance emphasise structured lifestyle support alongside pharmacotherapy for South Asian metabolic risk. Document HbA1c, waist circumference, and weight trends for follow-up visits in metro and tier-2 Indian practice. ## When do RSSDI pathways add GLP-1 after DPP-4? Specialists may escalate to GLP-1 when HbA1c remains above target on metformin plus DPP-4 despite structured lifestyle support. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised decisions. Kesho provides drug-class education only—not prescribing advice. Verify CDSCO approval and Schedule H prescriptions at licensed Indian pharmacies before every refill. RSSDI and ICMR guidance emphasise structured lifestyle support alongside pharmacotherapy for South Asian metabolic risk. Document HbA1c, waist circumference, and weight trends for follow-up visits in metro and tier-2 Indian practice. ## Can both drug classes be combined? Combination use occurs in selected patients under endocrinologist supervision—not self-directed stacking from pharmacy advice. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised decisions. Kesho provides drug-class education only—not prescribing advice. Verify CDSCO approval and Schedule H prescriptions at licensed Indian pharmacies before every refill. RSSDI and ICMR guidance emphasise structured lifestyle support alongside pharmacotherapy for South Asian metabolic risk. Document HbA1c, waist circumference, and weight trends for follow-up visits in metro and tier-2 Indian practice. ## How do oral options compare? Oral semaglutide and daily gliptin tablets suit different adherence profiles—empty-stomach rules differ from once-daily gliptin with meals. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised decisions. Kesho provides drug-class education only—not prescribing advice. Verify CDSCO approval and Schedule H prescriptions at licensed Indian pharmacies before every refill. RSSDI and ICMR guidance emphasise structured lifestyle support alongside pharmacotherapy for South Asian metabolic risk. Document HbA1c, waist circumference, and weight trends for follow-up visits in metro and tier-2 Indian practice. ## What lab monitoring applies to both classes? Quarterly HbA1c and annual kidney panels apply to both classes per RSSDI follow-up norms. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised decisions. Kesho provides drug-class education only—not prescribing advice. Verify CDSCO approval and Schedule H prescriptions at licensed Indian pharmacies before every refill. RSSDI and ICMR guidance emphasise structured lifestyle support alongside pharmacotherapy for South Asian metabolic risk. Document HbA1c, waist circumference, and weight trends for follow-up visits in metro and tier-2 Indian practice. ## Where is the full diabetes combination guide on Kesho? Our diabetes combination guide expands SGLT2, metformin, and GLP-1 pathways with Indian references. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised decisions. Kesho provides drug-class education only—not prescribing advice. Verify CDSCO approval and Schedule H prescriptions at licensed Indian pharmacies before every refill. RSSDI and ICMR guidance emphasise structured lifestyle support alongside pharmacotherapy for South Asian metabolic risk. Document HbA1c, waist circumference, and weight trends for follow-up visits in metro and tier-2 Indian practice. ## Quick questions ### Is GLP-1 vs DPP-4 India information on Kesho medical advice? No. Kesho provides drug-class education only. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised treatment decisions. ### Where is the full guide? See our complete medically reviewed guide linked on this page for in-depth coverage with references and India-specific context. ### What is the short answer on glp-1 vs dpp-4 india? DPP-4 inhibitors (gliptins) are oral, weight-neutral diabetes medicines with low hypoglycaemia risk—often first add-ons after metformin. GLP-1 receptor agonists deliver stronger weight and HbA1c effects but cost more and require injection or strict oral semaglutide rules. RSSDI pathways guide escalation under specialist supervision. ## Complete guide [glp-1-and-other-diabetes-meds](https://www.kesho.health/blog/glp-1-and-other-diabetes-meds) · [MD](https://www.kesho.health/md/blog/glp-1-and-other-diabetes-meds) ## Related guides - [GLP-1 vs metformin in India — when doctors combine or switch](https://www.kesho.health/compare/glp-1-vs-metformin) - [GLP-1 and Metformin Combination](https://www.kesho.health/keywords/glp-1-metformin-combination) - [GLP-1 Second Line Diabetes](https://www.kesho.health/keywords/glp-1-second-line-diabetes) --- *Drug-class education only — not medical advice. [Kesho](https://www.kesho.health)*